Phase III randomized, open label study (ARCHER 1050) of first-line dacomitinib (D) versus gefitinib (G) for advanced (adv) non-small cell lung cancer (NSCLC) in patients (pts) with epidermal growth factor receptor (<i>EGFR</i>) activating mutation(s).

Mok, Tony; Nakagawa, Kazuhiko; Rosell, Rafael; Wu, Yi‐Long; W. Trygstad, Carl; L. Capizzi, Robert; Young Lee, Min; Tsuji, Fumito; DeBenedetto, R.; Goldberg, Zelanna; Wang, Tao; Liang, Jane; P. Letrent, Stephen; O’Connell, Joseph; Antic, Vladan

doi:10.1200/jco.2013.31.15_suppl.tps8123

Public

Phase III randomized, open label study (ARCHER 1050) of first-line dacomitinib (D) versus gefitinib (G) for advanced (adv) non-small cell lung cancer (NSCLC) in patients (pts) with epidermal growth factor receptor (<i>EGFR</i>) activating mutation(s).

Shared by NobleBlocks on May 20, 2013 • 12:00 AM UTC

Authors:

Tony Mok

Kazuhiko Nakagawa

Rafael Rosell

Abstract

TPS8123 Background: D is an orally available, potent and selective irreversible small molecule inhibitor of all catalytically active members of the HER (human epidermal growth factor receptor) family tyrosine kinases that has shown activity in preclinical studies on EGFR mutant cell lines, including...

Subject

Medicine

T790M

Gefitinib

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!